Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

  1. Bertolotto, A.
  2. Arroyo, R.
  3. Celius, E.G.
  4. Comi, G.
  5. Havrdova, E.K.
  6. Honeycutt, W.D.
  7. Hunter, S.F.
  8. Izquierdo, G.
  9. Kornek, B.
  10. Miller, T.
  11. Mitsikostas, D.D.
  12. Singer, B.A.
  13. Ziemssen, T.
  14. Chung, L.
  15. Daizadeh, N.
  16. Afsar, S.
  17. Hashemi, L.
  18. Senior, P.
Revue:
Neurology and Therapy

ISSN: 2193-6536,  2193-8253

Année de publication: 2020

Volumen: 9

Número: 2

Pages: 443-457

Type: Article

DOI: 10.1007/S40120-020-00191-7 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus